337. ホモシスチン尿症 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 21 / 薬物数 : 22 - (DrugBank : 10) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 32

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
2-[4-[(2-amino-5-methyl-4-OXO-1,6,7,8-tetrahydropteridin-6-YL)methylam INO]benzoyl]amino
   Zambon Group S.p.A
      2007   -   EUCTR2006-000614-21-AT   Austria;Hungary;Italy;United Kingdom
      2006   Phase 2   EUCTR2006-000614-21-SK   Austria;Hungary;Slovakia;United Kingdom
      2006   Phase 2   EUCTR2006-000614-21-HU   Austria;Hungary;Slovakia;United Kingdom
      2006   -   EUCTR2006-000614-21-GB   Austria;Hungary;Italy;United Kingdom
5-mthf
   Zambon Group S.p.A
      2007   -   EUCTR2006-000614-21-AT   Austria;Hungary;Italy;United Kingdom
      2006   Phase 2   EUCTR2006-000614-21-SK   Austria;Hungary;Slovakia;United Kingdom
      2006   Phase 2   EUCTR2006-000614-21-HU   Austria;Hungary;Slovakia;United Kingdom
      2006   -   EUCTR2006-000614-21-GB   Austria;Hungary;Italy;United Kingdom
Acetaminophen
   Hospital de Clinicas de Porto Alegre
      2022   Phase 1/Phase 2   NCT04015557   Brazil
ACN00177
   Aeglea Biotherapeutics, Inc.
      2020   Phase 1   EUCTR2019-004791-19-GB   United Kingdom
Betaine
   Assistance Publique - Hôpitaux de Paris
      2015   Phase 2   NCT02404337   France
Creatine
   University of British Columbia
      2024   -   NCT06495567   Canada
Cysteine
   Hamad Medical Corporation
      2024   -   NCT06622577   Qatar
Detoxifying agents FOR antineoplastic treatment
   ZAMBON GROUP
      2006   -   EUCTR2006-000614-21-IT   Austria;Hungary;Italy;United Kingdom
Dietary methionine tracer and protein intake
   University of British Columbia
      2024   -   NCT06495567   Canada
EPI-743
   Bambino Gesù Hospital and Research Institute
      2013   Phase 2   NCT01793090   Italy
Methylenetetrahydrofolate reductase (mthfr) deficiency
   Istanbul Medeniyet University
      2019   -   NCT04287881   Turkey
N-acetylcysteine
   Hospital de Clinicas de Porto Alegre
      2022   Phase 1/Phase 2   NCT04015557   Brazil
   McGill University Health Center
      2007   Phase 2   NCT00483314   Canada
PEG
   Zhengzhou Children's Hospital
      2022   Phase 4   ChiCTR2100054613   China
Pegtarviliase IV
   Aeglea Biotherapeutics
      2021   Phase 1/Phase 2   NCT05154890   Australia;United Kingdom;United States
Pegtarviliase SC
   Aeglea Biotherapeutics
      2021   Phase 1/Phase 2   NCT05154890   Australia;United Kingdom;United States
Pegtibatinase
   Travere Therapeutics, Inc.
      2024   Phase 3   NCT06431893   United States
      2023   Phase 3   NCT06247085   United States
      2019   Phase 1/Phase 2   NCT03406611   United States
PKU express plus
   Vitaflo International, Ltd
      2021   -   NCT05051657   United Kingdom
Prefolic
   Zambon Group S.p.A
      2007   -   EUCTR2006-000614-21-AT   Austria;Hungary;Italy;United Kingdom
      2006   Phase 2   EUCTR2006-000614-21-SK   Austria;Hungary;Slovakia;United Kingdom
      2006   Phase 2   EUCTR2006-000614-21-HU   Austria;Hungary;Slovakia;United Kingdom
      2006   -   EUCTR2006-000614-21-GB   Austria;Hungary;Italy;United Kingdom
Prefolic 15*30CPR gastror 15MG
   ZAMBON GROUP
      2006   -   EUCTR2006-000614-21-IT   Austria;Hungary;Italy;United Kingdom
Rhgh
   Zhengzhou Children's Hospital
      2022   Phase 4   ChiCTR2100054613   China
SYNB1353
   Synlogic
      2022   Phase 1   NCT05462132   United States
Taurine
   University of Colorado, Denver
      2010   Phase 1/Phase 2   NCT01192828   United States